Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors.
Authors
Robin Kate Kelley
University of California, San Francisco, San Francisco, CA
Robin Kate Kelley , Eric Van Cutsem , Michael S. Lee , Ido Wolf , Marwan Fakih , Judith de Vos-Geelen , Valerie Lee , Arndt Vogel , Xi Lawrence Wu , Fan Jin , Girish S. Naik , Eileen Mary O'Reilly
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04976634
DOI
10.1200/JCO.2022.40.4_suppl.TPS669
Abstract #
TPS669
Poster Bd #
N1
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors.
First Author: Robin Kate Kelley
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Phase 2 study of pembrolizumab plus lenvatinib and belzutifan in patients with metastatic esophageal squamous cell carcinoma.
First Author: Carlos Rojas
Poster
2020 Gastrointestinal Cancers Symposium
An open-label phase II study of lenvatinib plus pembrolizumab in patients with advanced gastric cancer (EPOC1706).
First Author: Akihito Kawazoe
Poster
2022 ASCO Annual Meeting
Phase 1 LITESPARK-001 (MK-6482-001) study of belzutifan in advanced solid tumors: Update of the clear cell renal cell carcinoma (ccRCC) cohort with more than 3 years of total follow-up.
First Author: Eric Jonasch